Anbio Biotechnology Class A Ordinary Shares (NNNN) - Total Liabilities
Based on the latest financial reports, Anbio Biotechnology Class A Ordinary Shares (NNNN) has total liabilities worth $87.84K USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Anbio Biotechnology Class A Ordinary Shares - Total Liabilities Trend (2021–2025)
This chart illustrates how Anbio Biotechnology Class A Ordinary Shares's total liabilities have evolved over time, based on quarterly financial data. See Anbio Biotechnology Class A Ordinary Sha (NNNN) working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Anbio Biotechnology Class A Ordinary Shares Competitors by Total Liabilities
The table below lists competitors of Anbio Biotechnology Class A Ordinary Shares ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Admie Holding S.A
AT:ADMIE
|
Greece | €3.19 Billion |
|
Manitou BF S.A.
PA:MTU
|
France | €1.06 Billion |
|
Quanta Storage
TWO:6188
|
Taiwan | NT$5.08 Billion |
|
Haining China Leather Market Co Ltd
SHE:002344
|
China | CN¥4.54 Billion |
|
Qt Group Oyj
HE:QTCOM
|
Finland | €57.63 Million |
|
Shanghai Xinhua Media Co Ltd
SHG:600825
|
China | CN¥1.42 Billion |
|
Shanxi Zhendong Pharmaceutical
SHE:300158
|
China | CN¥882.65 Million |
|
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
SHG:688505
|
China | CN¥273.93 Million |
Liability Composition Analysis (2021–2025)
This chart breaks down Anbio Biotechnology Class A Ordinary Shares's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see NNNN company net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 344.31 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.00 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.00 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Anbio Biotechnology Class A Ordinary Shares's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Anbio Biotechnology Class A Ordinary Shares (2021–2025)
The table below shows the annual total liabilities of Anbio Biotechnology Class A Ordinary Shares from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $87.84K | -94.92% |
| 2024-12-31 | $1.73 Million | +74.23% |
| 2023-12-31 | $993.06K | -29.63% |
| 2022-12-31 | $1.41 Million | -40.70% |
| 2021-12-31 | $2.38 Million | -- |
About Anbio Biotechnology Class A Ordinary Shares
Anbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, and internationally. The company offers lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification, SHA dry chemistry, chemiluminescence immunoassay, and real-time polymerase chain reaction solutions; and SARS-CoV-2 and SARS-CoV-2/… Read more